Exploring the matrix to uncover hidden drivers of ovarian cancer

// Biomedical Engineering

Tags: Faculty, research

Image of collagen fibers in cancerous tissue

An image of collagen fibers in cancerous tissue. Professor Paul Campagnola employed a novel technique using second-harmonic generation microscopy to capture the image. Image courtesy of Paul Campagnola.

Share this story:

To form tissues, cells secrete molecules that create structure. But these molecules, known collectively as the extracellular matrix, do more than simply hold everything together. The extracellular matrix guides cell behavior, ordering changes that in turn cause cells to secrete different molecules—thereby changing the matrix itself.

So when tissue turns cancerous, the extracellular matrix is part of that overhaul, too. But what exactly changes—and the importance of those changes—isn’t yet clear.

Now, a team of University of Wisconsin-Madison biomedical engineers hopes to identify the specific extracellular matrix alterations that drive ovarian cancer progression while developing approaches to create representative in vitro models that could translate to study other forms of cancer.

The team has received a five-year, $2.2 million grant from the National Institutes of Health through the National Cancer Institute’s Cancer Tissue Engineering Collaborative Research Program.

Associate Professor Pam Kreeger, Vilas Distinguished Professor Kristyn Masters and Professor Paul Campagnola will analyze and then model high-grade serous ovarian cancer at different stages of the disease, from onset in the fallopian tube to metastasis in the ovary and further spread in the abdomen. It will provide the deepest look at the extracellular matrix in ovarian cancer to date.

Image of collagen fibers in normal tissue
An image of collagen fibers in normal tissue. Image courtesy of Paul Campagnola.

“Not only will we learn something about the different stages of ovarian cancer,” says Kreeger, “but more broadly, we will contribute to the goal of this NIH program by developing technologies that can then be used to study the matrix in other cancers.”

First, to characterize how the extracellular matrix changes in ovarian cancer, the group will examine normal and diseased tissue through two distinct methods. Campagnola, an expert in imaging the extracellular matrix, will employ a novel technique using second-harmonic generation microscopy to create 3D images that will reveal the physical structure of the matrix and the shape and alignment of the fibers inside.

To identify the matrix’s chemical components, the UW-Madison team will turn to Alexandra Naba, an assistant professor in the Department of Physiology and Biophysics at the University of Illinois at Chicago. Naba has experience conducting proteomic analysis—identifying all the proteins present—in the extracellular matrix through a technique called mass spectrometry.

“Then the question is, how do these differences in structure and composition impact the tumor?” Kreeger says.

To answer that, the researchers will replicate the extracellular matrix at different stages of the disease using both “bottom-up” and “top-down” approaches.

For the former, they’ll take the proteomic information and reconstruct the variation in the extracellular matrix from individual components. Campagnola can also micropattern the structures he sees to account for the physical dimensions.

In the “top-down” tactic, they’ll lean on Masters’ expertise in taking intact tissues and genetically manipulating the cells to over-express or inhibit certain proteins.

“When you build anything from scratch in the lab, it will never look like the native tissue,” says Masters, who has predominantly worked on cardiovascular diseases. “With this approach we can retain the richness and complexity of a native tissue, but manipulate the extracellular matrix.”

Both types of models will allow the group to assess the impacts of different extracellular matrix variations—in composition and in structure—on cancer cell proliferation and migration, as well as sensitivity to chemotherapy.

“We’re still in the early stages of understanding ovarian cancer progression,” says Kreeger. “Currently, the best predictor of outcome in ovarian cancer is how much of the disease they remove at your first surgery. However, if we can understand the environments of the tumors we have to leave behind, maybe we can give better outcomes for those patients.”

Kreeger, Masters and Campagnola are also members of the UW Carbone Cancer Center at UW-Madison. The team also includes two collaborators from the UW School of Medicine and Public Health: Paul Weisman, an assistant professor in the Department of Pathology and Laboratory Medicine, and Manish Patankar, a professor in the Department of Obstetrics and Gynecology.

Author: Tom Ziemer